Cargando…
Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent
Activating mutations in full length anaplastic lymphoma kinase (ALK) have been reported in neuroblastoma and in anaplastic thyroid cancer. ALK-L1198F and ALK-G1201E mutations were originally identified in anaplastic thyroid cancer (ATC) and characterized as constitutively activating mutations. In th...
Autores principales: | Guan, Jikui, Wolfstetter, Georg, Siaw, Joachim, Chand, Damini, Hugosson, Fredrik, Palmer, Ruth H, Hallberg, Bengt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355286/ https://www.ncbi.nlm.nih.gov/pubmed/28030793 http://dx.doi.org/10.18632/oncotarget.14141 |
Ejemplares similares
-
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
por: Guan, Jikui, et al.
Publicado: (2015) -
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
por: Siaw, Joachim T., et al.
Publicado: (2016) -
Targeting anaplastic lymphoma kinase in neuroblastoma
por: Umapathy, Ganesh, et al.
Publicado: (2019) -
Anaplastic lymphoma kinase: signalling in development and disease
por: Palmer, Ruth H., et al.
Publicado: (2009) -
Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells
por: Sattu, Kamaraj, et al.
Publicado: (2013)